Company: TVRD
Filing Date: 2025-02-14
Form Type: S-4/A
Source: 0001104659-25-013053
Chunk: 944

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-02-14
Form: S-4/A
Chunk 944
---
 |
|:------------------------|:--|:--|:-------|:--|----:|:--|:--|
| 2025                    | ​ | ​ | ​      | ​ |  63 | ​ | ​ |
| 2026                    | ​ | ​ | ​      | ​ |  63 | ​ | ​ |
| 2027                    | ​ | ​ | ​      | ​ |  63 | ​ | ​ |
| 2028                    | ​ | ​ | ​      | ​ |  63 | ​ | ​ |
| Thereafter              | ​ | ​ | ​      | ​ | 133 | ​ | ​ |
| Total                   | ​ | ​ | ​      | $ | 401 | ​ | ​ |

The Company recognized less than $0.1 million for amortization expense for each of the nine months ended September 30, 2024 and 2023. Amortization expense is included in research and development expense in the statements of operations.

F-123

TABLE OF CONTENTS

Tvardi Therapeutics, Inc. Notes to CONDENSED Financial Statements
(Unaudited) 6. Accrued Expenses Accrued expenses consisted of the following as of September 30, 2024 and December 31, 2023 (in thousands):

| ​                                          | ​ | ​ | As ofSeptember 30,2024 |   |       |   | ​ | ​ | As ofDecember 31,2023 |   |       |   | ​ |
|:-------------------------------------------|:--|:--|:-----------------------|:--|------:|:--|:--|:--|:----------------------|:--|------:|:--|:--|
| Accrued research and development expenses  | ​ | ​ | ​                      | $ | 1,008 | ​ | ​ | ​ | ​                     | $ |   574 | ​ | ​ |
| Accrued employee compensation and benefits | ​ | ​ | ​                      | ​ | 1,185 | ​ | ​ | ​ | ​                     | ​ |   942 | ​ | ​ |
| Other accrued expenses                     | ​ | ​ | ​                      | ​ | 1,044 | ​ | ​ | ​ | ​                     | ​ |    61 | ​ | ​ |
| Total accrued expenses                     | ​ | ​ | ​                      | $ | 3,237 | ​ |